IMPORTANT UPDATE
The Court has approved the distribution of the net settlement fund to eligible Court-approved Claimants who qualified for an award under the Plan of Allocation. In accordance with the Court’s September 8, 2021 Order, the initial distribution of the net settlement fund took place on October 28, 2021. If you have any questions regarding the distribution, please contact JND by calling 844-961-0316 or by sending an e-mail to Info@EndoSecuritiesLitigationSettlement.com. .

The information contained on this website is only a summary of the information presented in more detail in the Notice of (I) Pendency of Class Action and Proposed Settlement; (II) Motion for an Award of Attorneys' Fees and Reimbursement of Litigation Expenses; and (III) Settlement Fairness Hearing ("Notice"). Because this website is just a summary, you should review the Notice and Frequently Asked Questions for additional details.

Summary of the Action and Settlement

The Notice relates to a settlement of claims in a securities class action brought by an Endo investor alleging, among other things, that Endo International plc and Endo Health Solutions Inc. (together, “Endo”) and certain of Endo’s former employees and officers (collectively, “Defendants") violated the federal securities laws by making false and misleading statements and failing to disclose material adverse facts regarding the putative safety and abuse-deterrent properties of Reformulated Opana ER. Defendants deny all allegations of wrongdoing or liability whatsoever. A more detailed description of the Action is set forth in the Notice.

Court-appointed Lead Plaintiff SEB Investment Management AB, on behalf of itself and the Settlement Class, reached a settlement of the Action with Defendants for $82,500,000 in cash ("Settlement"). The Settlement resolves all claims of the Settlement Class in the Action. Following a hearing on December 11, 2019, the Court entered its Findings of Fact and Conclusions of Law approving the Settlement and resolving all claims in the Action, approving the Plan of Allocation for the proceeds of the Settlement, and awarding Lead Counsel attorneys’ fees and expenses. You can view the Court’s Findings of Fact and Conclusions of Law on the Important Documents tab of this website.

The Settlement Class consists of:

All persons and entities who purchased or otherwise acquired Endo common stock or ordinary shares between November 30, 2012 and June 8, 2017, inclusive, and were damaged thereby. Certain persons and entities are excluded from the Settlement Class by definition (see ¶ 20 of the Notice).

How do I obtain more information?

Detailed information about the Action and the Settlement is contained in the Notice. Additional information can also be obtained by contacting the Claims Administrator by calling toll-free 1-844-961-0316; emailing Info@EndoSecuritiesLitigationSettlement.com; or mailing a letter to:

Inquiries should NOT be directed to the Court or the Clerk of the Court.